ProCE Banner Activity

Expert Perspectives on TROP-2–Targeting ADCs for Advanced NSCLC

Clinical Thought

Read this commentary that captures our recent “Xtorial” with an expert interacting with healthcare professionals on the potential role of TROP-2–targeting ADCs in the treatment of patients with advanced NSCLC.

Released: July 15, 2024

Expiration: July 14, 2025

Share

Faculty

Narjust Florez

Narjust Florez, MD

Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Associate Editor, JAMA Oncology
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Narjust Florez, MD

Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Associate Editor, JAMA Oncology
Boston, Massachusetts

Narjust Florez, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, DSI, Janssen, Merck, Mirati, Novocure, Pfizer, Regeneron.